Background: Interleukin-28B (IL28B) locus on a human chromosomal region mapped to 19q13 execute
immune defense against viruses. During Hepatitis C Virus (HCV) infection the IL28B has a promising role in deciding
the consequence of infection for spontaneous clearance of viruses or causing chronic liver infection. Treatment of
chronic hepatitis C includes use of direct acting antivirals, Pegylated-Interferon (PEG-IFN) and Ribavirin (RBV)
therapy. Also, interferon free regimens are suggested to be useful in resistant patients. Numerous reports including
Genome-Wide Association Studies (GWAS), comprehensive meta-analysis and independent case-control studies in
different population have revealed the association between certain Il-28B polymorphisms and response to the PEGIFN-
RBV therapy in patients infected with HCV.
Method: We searched all peer-reviewed relevant and recent literature manually for the present review.
Conclusion: The GWAS studies have revealed an important role of IL28B in HCV infection, which was supported
by many independent studies and meta-analysis by different groups in different ethnicities. IL28B genotyping may be
use as predictors of response for IFN-based therapy and personalized treatment of hepatitis C patient.